<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> and myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) is a distinctive clinical syndrome occurring after exposure to chemotherapy (CT) or radiotherapy (RT) </plain></SENT>
<SENT sid="1" pm="."><plain>We report findings on 306 consecutive patients referred to our institution with morphologic review and cytogenetic analyses </plain></SENT>
<SENT sid="2" pm="."><plain>Since 1972, 141 males and 165 females with a median age of 51 years (range, 3-83 years) at primary diagnosis and 58 years (range, 6-86 years) at secondary diagnosis were analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>Patients had been administered various cytotoxic agents, including <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> (240 patients, 78%) and topoisomerase 2 inhibitors (115 patients, 39%) </plain></SENT>
<SENT sid="4" pm="."><plain>One hundred twenty-one (40%) had undergone CT alone, 43 (14%) had undergone RT alone, and 139 (45%) had undergone both modalities </plain></SENT>
<SENT sid="5" pm="."><plain>At diagnosis of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 282 (92%) had clonal abnormalities involving chromosome 5 (n = 63), chromosome 7 (n = 85), chromosomes 5 and 7 (n = 66), recurring balanced rearrangements (n = 31), other clonal abnormalities (n = 39), or <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype (n = 24) </plain></SENT>
<SENT sid="6" pm="."><plain>Abnormalities of chromosome 5, 7, or both accounted for 76% of <z:hpo ids='HP_0000001'>all</z:hpo> cases with an abnormal karyotype </plain></SENT>
<SENT sid="7" pm="."><plain>Seventeen patients acquired t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after autologous stem cell transplantation, but no unique pattern of cytogenetic abnormalities was observed </plain></SENT>
<SENT sid="8" pm="."><plain>Shorter latency was observed for patients with balanced rearrangements (median, 28 vs 67 months; P &lt;.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> were more likely to have balanced rearrangement than those with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (28% vs 4%; P &lt;.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>Median survival time after diagnosis of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was 8 months; survival at 5 years was less than 10% </plain></SENT>
<SENT sid="11" pm="."><plain>These data confirm and extend previous associations between clinical, morphologic, and cytogenetic findings in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>